GlassScriptPhysician profile
Autumn Bartenfield
NPI 1033425319
$3,394.86
in general payments reported to CMS, 2019-2025
32 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $610 · 2022: $549 · 2023: $1,544 · 2024: $335 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $391.90 | 2021-2023 | Xarelto |
| Pfizer INC. | $390.62 | 2021-2024 | |
| Boston Scientific Corporation | $369.58 | 2021-2025 | Wavewriter Alpha Prime 16, Watchman Flx, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $349.69 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $211.88 | 2021-2023 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.30 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $146.39 | 2021-2023 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.62 | 2024-2025 | Relistor |
| Amgen INC. | $135.20 | 2021-2024 | Repatha |
| United Therapeutics Corporation | $133.07 | 2022-2024 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.25 | 2021-2023 | Lifevest |
| Nalu Medical, INC. | $105.89 | 2024-2025 | Nalu Neurostimulation System |
| Merck Sharp & Dohme LLC | $91.80 | 2022-2023 | Verquvo |
| Novo Nordisk INC | $76.53 | 2022-2023 | Ozempic, Wegovy, Rybelsus |
| Foundation Fusion Solutions, LLC | $67.89 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $60.52 | 2023 | Inpefa |
| Medtronic, INC. | $41.32 | 2024-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Alnylam Pharmaceuticals INC. | $38.88 | 2022-2023 | Amvuttra |
| Astellas Pharma US INC | $35.46 | 2021 | |
| Amarin Pharma, INC. | $34.05 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $33.78 | 2025 | |
| Averitas Pharma INC. | $28.58 | 2025 | Qutenza |
| Preventice Services, LLC | $25.28 | 2021 | |
| Verona Pharma, INC. | $25.17 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $22.21 | 2024 | Evkeeza |
| Abbott Laboratories | $19.91 | 2024 | Diamondback Coronary |
| Kiniksa Pharmaceuticals, LTD. | $19.44 | 2023 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $19.02 | 2023 | Edarbyclor |
| Esperion Therapeutics, INC. | $16.30 | 2021 | |
| Valinor Pharma, LLC | $15.48 | 2025 | Movantik |
| Sanofi-Aventis U.S. LLC | $14.75 | 2023 | |
| Philips North America LLC | $14.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Autumn Bartenfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.